We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
+6.89%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$226M
AUM Growth
-$56.3M
(-20%)
Cap. Flow
-$64.5M
Cap. Flow
% of AUM
-28.59%
Top 10 Holdings %
Top 10 Hldgs %
96.72%
Holding
13
New
1
Increased
4
Reduced
7
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioNTech
BNTX
|
+$11.5M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
+$5.05M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$141K |
| 4 |
TARO
Taro Pharmaceutical Industries Ltd.
TARO
|
+$59.6K |
| 5 |
Sanofi
SNY
|
+$27.3K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$33.1M |
| 2 |
Alkermes
ALKS
|
+$18.8M |
| 3 |
United Therapeutics
UTHR
|
+$9.96M |
| 4 |
Exelixis
EXEL
|
+$7.4M |
| 5 |
Biogen
BIIB
|
+$6.19M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Exelixis
EXEL
$13.3B
| $37.2M | 16.48% |
1,566,140
-332,939
| -18% | -$7.4M |
|
|
2
United Therapeutics
UTHR
$25.8B
| $36M | 15.96% |
156,714
-44,158
| -22% | -$9.96M |
|
|
3
Biogen
BIIB
$30B
| $28.9M | 12.82% |
134,068
-26,412
| -16% | -$6.19M |
|
|
TARO
4
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $27.4M | 12.16% |
647,868
+1,415
| +0.2% | +$59.6K |
|
5
Cardinal Health
CAH
$53.9B
| $26.4M | 11.69% |
235,656
-45,820
| -16% | -$4.94M |
|
|
6
Enanta Pharmaceuticals
ENTA
$366M
| $19.6M | 8.71% |
1,124,586
+381,762
| +51% | +$5.05M |
|
|
7
Jazz Pharmaceuticals
JAZZ
$15.9B
| $12.2M | 5.4% |
101,151
+1,151
| +1% | +$141K |
|
|
8
Regeneron Pharmaceuticals
REGN
$78.5B
| $12M | 5.33% |
12,494
-34,762
| -74% | -$33.1M |
|
|
9
BioNTech
BNTX
$22.9B
| $11.1M | 4.91% |
+120,000
| New | +$11.5M |
|
|
10
Sanofi
SNY
$103B
| $7.34M | 3.25% |
150,959
+559
| +0.4% | +$27.3K |
|
|
11
Alkermes
ALKS
$8.22B
| $6.97M | 3.09% |
257,554
-660,484
| -72% | -$18.8M |
|
|
MURA
12
DELISTED
Mural Oncology
MURA
| $430K | 0.19% |
88,001
-2,832
| -3% | -$13.7K |
|
|
MASI
13
DELISTED
Masimo
MASI
| – | – |
-8,000
| Closed | -$938K |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q1 2024 Portfolio in Review
As of Q1 2024, Krensavage Asset Management held 13 positions worth $226M, down 20% from $282M the previous quarter. Its ten largest holdings account for 97% of the portfolio.
Krensavage Asset Management withdrew a net $64.5M in Q1 2024, closing 1 position and reducing 7 holdings. Its most notable exit was Masimo, an estimated $938K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Krensavage Asset Management opened a new position in BioNTech worth $11.1M.
- Krensavage Asset Management's largest Q1 2024 buy was BioNTech: 120,000 shares worth $11.1M.
- Krensavage Asset Management added most to Enanta Pharmaceuticals in Q1 2024, an estimated $5.05M increase.
- Krensavage Asset Management's biggest Q1 2024 reduction was Regeneron Pharmaceuticals, cutting an estimated $33.1M.
- Krensavage Asset Management fully exited Masimo in Q1 2024, selling an estimated $938K.
- Krensavage Asset Management's ten largest holdings make up 97% of its $226M portfolio in Q1 2024.
- Krensavage Asset Management opened 1 new position and closed 1 in Q1 2024.
- Krensavage Asset Management's portfolio value fell 20% quarter-over-quarter to $226M.
Based on Krensavage Asset Management's 13F filing for Q1 2024, filed 15 May 2024.